Across TCGA pan-cancer cohorts, DNTTIP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DNTTIP2 data layer compared with 23 for mass-spec protein and 8 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DNTTIP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNTTIP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
STAD, LUSC, and UCEC are the cancer types where DNTTIP2 Mutation most reproducibly stratifies survival.